Physician profile
Amy M Murphy
NPI 1891984977
$5,123.71
in general payments reported to CMS, 2019-2025
29 companies · $904 in 2025
The $904 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $646 · 2022: $941 · 2023: $1,119 · 2024: $1,514 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,179 · Education: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,178.86 |
| Education | $358.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,144.33 | 2021-2025 | |
| Janssen Biotech, INC. | $713.20 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Regeneron Healthcare Solutions, INC. | $547.54 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $367.38 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $290.04 | 2021-2025 | Blu-U, Ilumya |
| Amgen INC. | $285.06 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $245.07 | 2021-2025 | |
| Leo Pharma INC. | $221.33 | 2022-2025 | Adbry |
| Lilly USA, LLC | $188.77 | 2021-2025 | Taltz, Ebglyss |
| Almirall LLC | $139.00 | 2021-2025 | Seysara, Klisyri |
| Ucb, INC. | $116.39 | 2021-2024 | Bimzelx |
| Incyte Corporation | $115.27 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $84.86 | 2022-2024 | Sotyktu |
| Genentech USA, INC. | $75.03 | 2021-2024 | Xolair |
| Pfizer INC. | $68.25 | 2022-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $57.14 | 2022 | |
| Merz North America, INC. | $50.89 | 2022-2023 | Xeomin |
| Helsinn Therapeutics (U.S.), INC. | $50.18 | 2023-2024 | Valchlor |
| Novo Nordisk INC | $50.00 | 2021 | |
| Gilead Sciences, INC. | $49.50 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.40 | 2023 | Spevigo |
| Biofrontera INC. | $46.18 | 2025 | Ameluz, Bf-Rhodoled, Rhodoled Xl |
| Galderma Laboratories, L.P. | $45.40 | 2024-2025 | Nemluvio |
| Kyowa Kirin, INC. | $24.85 | 2024 | Poteligeo |
| Organogenesis INC. | $23.35 | 2023 | Puraply |
| Dermavant Sciences, INC. | $22.44 | 2022 | |
| Arcutis Biotherapeutics, INC. | $20.78 | 2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $18.17 | 2021 | |
| Strata Skin Sciences, INC. | $13.91 | 2023 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.